

Lipopharma selected one of the 8 best 2013 Health Care projects in Europe at the European Venture Summit 2013

- ✓ *Lipopharma's project was awarded as one of the 8 best European projects in the Health Care space selected by a prestigious panel of 28 directives of pharmaceutical companies and Venture Capital Funds specialized in healthcare investments at the final session of the European Venture Summit, held on the 9th & 10th December 2013 in Düsseldorf (Germany)*
- ✓ *The presentation made by Vicenç Tur, Lipopharma's CEO, was focused on the applications of 2OHOA as a potential innovative drug for the treatment of malignant brain tumours (glioma) and included preliminary results of the MIN-001-1203 clinical study currently on-going.*

Palma de Mallorca, December, 10th 2013. Lipopharma presented yesterday 2OHOA as a new innovative drug for the potential treatment of glioma in the course of the final sessions of the European Venture Contest (EVC) 2013. 23 leading European biotech companies, previously selected among the most innovative and with the most promising prospects in the European biopharmaceutical market, presented their projects in front of a qualified panel of 28 European VC investors specialized in Biotech projects and directives of pharmaceutical companies, including GlaxoSmithKline (GSK), Boehringer Ingelheim (BI) or DSM. **Lipopharma's project was selected as one of the best 8 biotech projects in Europe in 2013.**

The **European Venture Summit** is the final session of the prestigious **European Venture Contest** organized by Europe Unlimited with the objective of finding, evaluating and awarding world-class innovative companies with the potential to dramatically impact their industry and contribute to increasing European competitiveness and growth by providing access to top-level international partners, advisors and financiers. The Contest, this year in its 9th edition, gathered over 800 companies and 600 venture capitalist and corporate investors from all over Europe. The Top 120 companies awarded at the qualifier events presented at the European Venture Summit and the Top 25 were selected

The European Venture Summit was organised at the Congress Centre Düsseldorf and hosted by the City of Düsseldorf and the Ministry of Innovation, Science and Research of the German State of North Rhine Westphalia. The European Venture Summit was sponsored by NRW.Bank, Mobicap Ventures, and DealMarket and supported by BondPR and EMMINVEST. The Contest Jury, composed of 19 international investors and 28 investors with extensive experience in their respective fields elected the best 25 presenting companies (9 ICT, 8 life sciences and 8 cleantech) from more than 100 companies qualified through EVC 2013 Semi-Finals.



EVC EUROPEAN VENTURE CONTEST 2013

It is the pleasure of the Forum Organisers to grant

Lipopharma Therapeutics

BEST PRESENTATION AWARD
For a high quality presentation as evaluated by a panel of International Expert Reviewers

William Stevens
Founder & Chairman
Europe Unlimited
On the behalf of
Forum Organisers

HOSTS: City of Düsseldorf, Ministry of Innovation, Science and Research of the German State of North Rhine Westphalia

SILVER SPONSORS: NRW.BANK, mobicap VENTURES, DEALMARKET

GLOBAL PARTNER: bondPR

SUPPORTED BY: EMMINVEST

ORGANIZED BY: EUROPE UNLIMITED

Contact:

Lipopharma

Ctra. Valldemossa, Km. 7,4. ParcBIT. Edif. 17. 2nd. C-8. E07121 – Palma de Mallorca. Spain.
Tel. (+34) 971 439 886 :: Email: info@lipopharma.com :: www.lipopharma.com

ADDITIONAL INFORMATION

About 2OHOA

2OHOA (2-hydroxyoleic acid) is an orally bioavailable synthetic analog of the fatty acid oleic acid that selectively activates **sphingomyelin synthase (SMS)**, thereby increasing the concentration of sphingomyelin (**SM**), ceramide (**Cer**) and diacylglycerol (**DAG**) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signalling and the aberrant activity of signalling pathways in tumor cells, including the Ras/MAPK and PI3K/Akt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause selective cancer cell death by autophagy/apoptosis.

In pre-clinical studies, this compound has demonstrated marked anticancer effect with no apparent toxicity against some of the most lethal forms of cancer. Positive “proof of concept” studies of 2OHOA in animal models of human tumours of Glioma, NSCLC, Pancreas or Prostate are already available.

2OHOA has obtained the **Orphan Drug** designation by the EMA for the treatment of glioma in October 2011. A PI/IIa **clinical study** in glioma and other solid tumors (**MIN-001-1203**) is already on-going in the UK and Spain since May 2013, so far with very positive results.

About MLT

Membrane-Lipid Therapy (MLT) derives from a highly specialized scientific knowledge developed by Lipopharma's scientists and consists on the design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead of targeting cellular proteins. This innovative know-how is Lipopharma's main expertise and lays on new discoveries made by Lipopharma's scientists related to the role of membrane lipids and membrane lipid structure on the regulation of localization and activity of membrane signalling proteins.

About Lipopharma

Lipopharma is an innovative clinical stage biopharmaceutical company based in Palma de Mallorca (Spain) that specializes in the design and development of innovative pharmaceutical products aimed at the prevention and treatment of human pathologies. The design of molecules is based on structure-function principles according to the unique MLT know-how developed by Lipopharma's scientific team. Lipopharma is also developing a portfolio of new products based on the MLT with potential applications in fields such as neurodegenerative diseases, inflammation or cancer.

Disclaimer

Except for historical information, this press release may contain forward-looking statements, which reflect the companies' current expectations regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other financial, technical or market risks. All forward-looking statements are qualified in their entirety by this cautionary statement and Lipopharma Therapeutics SL does not undertake any obligation to revise or update this press release to reflect events or circumstances after the date hereof